Omeros (NASDAQ:OMER) Upgraded at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

Other equities research analysts also recently issued research reports about the stock. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Omeros Trading Up 41.1 %

Omeros stock opened at $10.91 on Wednesday. The firm has a market capitalization of $632.23 million, a P/E ratio of -4.10 and a beta of 1.47. The business has a 50-day moving average of $4.37 and a 200-day moving average of $4.18. Omeros has a 1 year low of $1.81 and a 1 year high of $10.99.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OMER. BNP Paribas Financial Markets raised its holdings in shares of Omeros by 75.5% during the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 12,951 shares during the period. Comerica Bank lifted its holdings in shares of Omeros by 20.0% in the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 5,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after buying an additional 81,348 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after buying an additional 31,081 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Omeros in the 2nd quarter valued at approximately $105,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.